肝脏 ›› 2024, Vol. 29 ›› Issue (10): 1265-1268.

• 代谢相关脂肪性肝病 • 上一篇    下一篇

慢性HBV感染合并非酒精性脂肪性肝病患者血清脂联素、ROS及糖脂代谢特征

董丹丹, 邱利, 胡毅   

  1. 430071 湖北 武汉市第七医院感染(肝病)科
  • 收稿日期:2024-05-17 出版日期:2024-10-31 发布日期:2024-12-02
  • 基金资助:
    武汉市卫健卫支助项目(EZ20C05)

Characteristics of serum adiponectin, ROS, and glucose-lipid metabolism in patients with chronic hepatitis B and concurrent non-alcoholic fatty liver disease

DONG Dan-dan, QIU Li, HU Yi   

  1. Department of Infection (Liver Disease), Seventh Hospital of Wuhan, Hubei 430071, China
  • Received:2024-05-17 Online:2024-10-31 Published:2024-12-02

摘要: 目的 分析慢性乙型肝炎病毒(HBV)感染合并非酒精性脂肪性肝病(NAFLD)患者血清脂联素(APN)、反应性氧化物(ROS)及糖脂代谢特征。方法 收集2022年4月—2024年4月期间在武汉市第七医院就诊的慢性HBV感染(HBV组,61例)、NAFLD(NAFLD 组,26例)、慢性HBV感染合并NAFLD(HBV+ NAFLD 组,85例)患者共计172例,分析患者的临床资料,检测并比较血清APN、ROS、糖脂代谢指标[空腹血糖(FPG)、空腹胰岛素(FINS)、稳态模型胰岛素抵抗指数(HOMA-IR)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)]、肝功能及肝纤维化指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、透明质酸(HA)、层黏连蛋白 (LN)、Ⅲ型前胶原肽(PⅢP)、Ⅳ型胶原(CⅣ)]变化。结果 NAFLD组FINS、HOMA-IR、TC、TG分别为(16.31±2.64)μIU/L、(4.08±0.69)、(5.22±1.23)mmol/L、(2.05±0.73)mmol/L,HBV+NAFLD组分别为(16.14±2.58)μIU/L、(4.09±0.71)、(4.72±1.21)mmol/L、(1.76±0.38)mmol/L,均显著高于HBV组的(9.03±1.25)μIU/L、(2.18±0.33)、(4.31±0.82)mmol/L、(1.16±0.32)mmol/L(P<0.05),但NAFLD组与HBV+NAFLD组间并未见显著差异(P>0.05)。三组的ALT、AST、HA、LN、PⅢP和CⅣ比较,差异均无统计学意义(P>0.05)。NAFLD组、HBV+NAFLD组的ROS分别为(2.05±0.43)U/mL、(1.89±0.38)U/mL,显著高于HBV组的(0.91±0.24)U/mL(P<0.05);NAFLD组、HBV+NAFLD组的APN分别为(8.02±1.15)ng/mL、(8.47±1.26)ng/mL,均显著低于HBV组的(10.14±2.33)ng/mL(P<0.05),但HBV+NAFLD组的ROS、APN与NAFLD组比较差异无统计学意义(P>0.05)。结论 APN低表达、ROS过表达和糖脂代谢异常可能参与慢性HBV感染合并NAFLD的病程进展。

关键词: 慢性乙型肝炎, 肝炎病毒, 非酒精性脂肪性肝病, 脂联素, 反应性氧化物, 血糖, 血脂

Abstract: Objective To analyze the characteristics of serum adiponectin (APN), reactive oxygen species (ROS), and glucose-lipid metabolism in patients with chronic hepatitis B virus (HBV) infection combined with non-alcoholic fatty liver disease (NAFLD). Methods Between April 2022 and April 2024, a total of 172 patients were enrolled, including those with chronic HBV infection (HBV group, 61 cases), NAFLD (NAFLD group, 26 cases), and chronic HBV infection combined with NAFLD (HBV+NAFLD group, 85 cases) . Clinical data were analyzed, and serum levels of APN, ROS, and glucose-lipid metabolism indicators_fasting blood glucose (FPG), fasting insulin (FINS), Homeostasis model assessment of insulin resistance(HOMA-IR), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG)-were measured. Liver function andfibrosis markers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), hyaluronic acid (HA), laminin (LN), type III procollagen peptide (PIIIP), and type IV collagen (CIV), were also assessed. Results The FINS, HOMA-IR, TC, and TG levels in the NAFLD group were (16.31±2.64) μIU/L,(4.08±0.69), (5.22±1.23) mmol/L, and (2.05±0.73) mmol/L respectively, In the HBV+NAFLD group, these values were (16.14±2.58) μIU/L, (4.09±0.71), (4.72±1.21) mmol/L, and (1.76±0.38) mmol/L respectively. Both the NAFLD and HBV+NAFLD groups showed significantly higher values compared to the HBV group, which had FINS, HOMA-IR, TC and TG levels of (9.03±1.25) μIU/L, (2.18±0.33), (4.31±0.82) mmol/L, and (1.16±0.32) mmol/L, respectively (P<0.05). However, no significant differences were observed between the NAFLD and HBV+NAFLD groups (P>0.05). There were no statistically significant differences in ALT, AST, HA, LN, P Ⅲ P, or CⅣ levels among the three groups (P>0.05). The ROS levels in the NAFLD group and HBV+NAFLD group were (2.05±0.43) U/mL and (1.89±0.38) U/mL respectively, both significantly higher than the HBV group at (0.91±0.24) U/mL (P<0.05). The APN levels in the NAFLD and HBV+NAFLD groups were (8.02±1.15) ng/mL and (8.47±1.26) ng/mL, respectively, significantly lower than the HBV group at (10.14±2.33) ng/mL (P<0.05). However, no statistically significant differences in ROS and APN levels were observed between the HBV+NAFLD and NAFLD group (P>0.05). Conclusion Low APN expression elevated ROS levels, and abnormal glucose-lipid metabolism may contribute to the progression of chronic HBV infection combined with NAFLD.

Key words: Chronic hepatitis B, Hepatitis virus, Non-alcoholic fatty liver disease, Adiponectin, Reactive oxides, Blood sugar, Blood fat